4588 — Oncolys Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- ¥14bn
- ¥13bn
- ¥63m
Annual cashflow statement for Oncolys Biopharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -909 | -2,091 | -1,612 | -1,146 | -1,936 |
| Depreciation | |||||
| Non-Cash Items | 481 | 765 | 351 | 13 | 22.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 186 | -144 | -488 | -585 | 574 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -238 | -1,465 | -1,742 | -1,717 | -1,337 |
| Capital Expenditures | -4.29 | -2.7 | -1.44 | -1.36 | -5.69 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.152 | -34.9 | 0.495 | 21.5 | 0.294 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -4.44 | -37.6 | -0.942 | 20.1 | -5.39 |
| Financing Cash Flow Items | -0.001 | -0.002 | 30.8 | -0.031 | 18.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1,123 | 242 | 3,091 | -114 | 1,143 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 879 | -1,275 | 1,387 | -1,743 | -178 |